| Code | CSB-RA868278MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to QX-004N, targeting interleukin-23 subunit alpha (IL23A), a critical cytokine component in inflammatory and immune responses. IL23A combines with IL12B to form the heterodimeric cytokine IL-23, which plays a pivotal role in the differentiation and maintenance of Th17 cells. This cytokine pathway is fundamentally involved in chronic inflammatory conditions, including psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. Dysregulated IL-23 signaling contributes to sustained inflammation and tissue damage in autoimmune disorders, making it an important therapeutic target for understanding disease mechanisms.
The reference antibody QX-004N represents a well-characterized research tool for investigating IL-23-mediated pathways and their contributions to inflammatory disease pathology. This biosimilar antibody provides researchers with a reliable reagent for studying IL23A function, cytokine signaling networks, and immune cell regulation in various experimental models. It serves as a valuable tool for immunology research, drug development studies, and mechanistic investigations of IL-23-driven pathological processes.
There are currently no reviews for this product.